MNOV MediciNova

MediciNova Announces Positive Findings on MN-001 (tipelukast) in Acute Liver Injury Model to be Presented at The Liver Meeting Digital Experience™ 2020

MediciNova Announces Positive Findings on MN-001 (tipelukast) in Acute Liver Injury Model to be Presented at The Liver Meeting Digital Experience™ 2020
EN
13/10/2020

Underlying

MNOVMediciNova

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MediciNova

 PRESS RELEASE
Free
MNOV MEDICINOVA

MediciNova Wins Contract Research and Development Innovation Award at ...

MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards LA JOLLA, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), announces that the company has been selected as a winner of the “Contract Research and Development Innovation Award” at the Fifth Annual BioTech Breakthrough Awards. MediciNova earned this recognition for its innovative work advancing MN-166 (ibudilast), the company’s le...

November 6, 2025 1 EN
 PRESS RELEASE
Free
MNOV MEDICINOVA

MediciNova Announces Completion of Patient Enrollment in MN-001-NATG-2...

MediciNova Announces Completion of Patient Enrollment in MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast) LA JOLLA, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announces the completion of patient enrollment in its Phase 2 clinical trial, MN-001-NATG-202, evaluating MN-001 (Tipelukast) for the treatment of hypertriglyceridemia and non-alcoholic fatty liver disease (NAFLD) due to Type 2 diabetes (T2DM). Patient recru...

November 4, 2025 1 EN
 PRESS RELEASE
Free
MNOV MEDICINOVA

MediciNova to Present at the LD Micro Main Event XIX Investor Conferen...

MediciNova to Present at the LD Micro Main Event XIX Investor Conference LA JOLLA, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the “Company”), announces that Yuichi Iwaki, M.D., Ph.D., President and CEO, and David H. Crean, Ph.D., Chief Business Officer, will present a corporate overview at the LD Micro Main Event XIX Investor Conference. The conference is being held on October 19 – 22, 2025 at the Hotel Del Coronado in San ...

October 6, 2025 1 EN
 PRESS RELEASE
Free
MNOV MEDICINOVA

MediciNova Announces Poster Presentation of COMBAT-ALS Clinical Trial ...

MediciNova Announces Poster Presentation of COMBAT-ALS Clinical Trial at the 36th International Symposium on ALS/MND LA JOLLA, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding the Phase 2b/3 COMBAT clinical trial of MN-166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS) patients has been selected for a poster presentation at 36th International Symposium on ALS/MND to be held December ...

September 16, 2025 1 EN
 PRESS RELEASE
Free
MNOV MEDICINOVA

MediciNova Provides Shareholder Update on Key Developments

MediciNova Provides Shareholder Update on Key Developments LA JOLLA, Calif., Sept. 08, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the “Company”), provides a shareholder update recapping important developments for the Company. Standby Equity Purchase Agreement (SEPA) The Company reported the signing of a Standby Equity Purchase Agreement (SEPA) for up to $30 million worth of common stock over the course of 36 months. Under that Agr...

September 8, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch